Drugs / Lutetium-177-PSMA-617
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06972628 | May 2025 → Apr 2027 expected | prostate carcinoma | Ebrahim S Delpassand | Recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-10-26 | Novartis Pharmaceuticals | Novartis confirms unconstrained supply for Pluvicto® and continues to significantly expand the number of treatment centers novartis.com ↗ |
| 2023-10-23 | Novartis Pharmaceuticals | Novartis Pluvicto™ shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane setting novartis.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lutetium-177-PSMA-617 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06972628 ↗ |
| Known as | Pluvicto | “The purpose of this study is to evaluate the safety and tolerability of Lutetium-177-PSMA-617 (PLUVICTO) in patients with metastatic castration-resistant prostate cancer...” NCT06972628 ↗ |
| Route | Intravenous | “PLUVICTO is administered via IV infusion over 2-5 minutes during each session.” NCT06972628 ↗ |